Search

Author/Creator Fletcher, Thomas E.

1. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Issue 3 (13th November 2021)

Authors:
Walker, Lauren E.; FitzGerald, Richard; Saunders, Geoffrey; Lyon, Rebecca; Fisher, Michael; Martin, Karen; Eberhart, Izabela; Woods, Christie; Ewings, Sean; Hale, Colin; Rajoli, Rajith K. R.; Else, Laura; Dilly‐Penchala, Sujan; Amara, Alieu; Lalloo, David G.; Jacobs, Michael; Pertinez, Henry; Hat...
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 111:Issue 3(2022)
Page Start:
585
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. (December 2021)

Authors:
Burel, Julie G.; Singhania, Akul; Dubelko, Paige; Muller, Julius; Tanner, Rachel; Parizotto, Eneida; Dedicoat, Martin; Fletcher, Thomas E.; Dunbar, James; Cunningham, Adam F.; Lindestam Arlehamn, Cecilia S.; Catanzaro, Donald G.; Catanzaro, Antonino; Rodwell, Timothy; McShane, Helen; O'Shea, Matt...
Journal:
Tuberculosis
Issue:
Volume 131(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search